Lower detection rates of SARS-COV2 antibodies in cancer patients vs healthcare workers after symptomatic COVID-19
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
The diagnosis of COVID-19 is based on the detection of the SARS-COV2 virus using RT-PCR from nasopharyngeal samples at the time of active infection (1, 2, 3). Most patients infected with SARS-COV2 develop antibodies (Ab) against SARS-COV2 proteins (1, 2, 3). The survival of cancer patients presenting with RT-PCR+ COVID-19 has been reported to be very poor, with up to 30% mortality at 30 days. In this work, we retrospectively analyzed cancer patients presenting with a suspicion of COVID-19 from March 1st 2020 to April 16th 2020 as part of an Institutional Review Board approved clinical trial (Oncovid-19, approved 12 March 2020) and a series of health care workers (HCWs, nurses and doctors) as part of a voluntary testing procedure in the Centre Leon Berard. (…)
Annals of Oncology , éditorial, 2019